174 related articles for article (PubMed ID: 24491043)
1. Role of CDH1 promoter polymorphism and DNA methylation in bladder carcinogenesis: a meta-analysis.
Wang Y; Kong CZ; Zhang Z; Yang CM; Li J
DNA Cell Biol; 2014 Apr; 33(4):205-16. PubMed ID: 24491043
[TBL] [Abstract][Full Text] [Related]
2. Role of CDH1 promoter methylation in colorectal carcinogenesis: a meta-analysis.
Li YX; Lu Y; Li CY; Yuan P; Lin SS
DNA Cell Biol; 2014 Jul; 33(7):455-62. PubMed ID: 24684676
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin gene promoter hypermethylation may contribute to the risk of bladder cancer among Asian populations.
Li G; Liu Y; Yin H; Zhang X; Mo X; Tang J; Chen W
Gene; 2014 Jan; 534(1):48-53. PubMed ID: 24404589
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation and polymorphism of E-cadherin gene may confer a risk to prostate cancer: a meta-analysis based on 22 studies.
Chang Z; Zhou H; Liu Y
Tumour Biol; 2014 Oct; 35(10):10503-13. PubMed ID: 25056535
[TBL] [Abstract][Full Text] [Related]
5. Association of genetic variants in and promoter hypermethylation of CDH1 with gastric cancer: a meta-analysis.
Jing H; Dai F; Zhao C; Yang J; Li L; Kota P; Mao L; Xiang K; Zheng C; Yang J
Medicine (Baltimore); 2014 Oct; 93(19):e107. PubMed ID: 25340495
[TBL] [Abstract][Full Text] [Related]
6. The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis.
Wang Q; Wang B; Zhang YM; Wang W
J Ovarian Res; 2016 Apr; 9():23. PubMed ID: 27067410
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance and potential drug targeting of CDH1 in lung cancer: a meta-analysis and literature review.
Yu Q; Guo Q; Chen L; Liu S
Drug Des Devel Ther; 2015; 9():2171-8. PubMed ID: 25931811
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.
Horikawa Y; Sugano K; Shigyo M; Yamamoto H; Nakazono M; Fujimoto H; Kanai Y; Hirohashi S; Kakizoe T; Habuchi T; Kato T
J Urol; 2003 Apr; 169(4):1541-5. PubMed ID: 12629411
[TBL] [Abstract][Full Text] [Related]
9. Role of RASSF1A promoter methylation in the pathogenesis of ovarian cancer: a meta-analysis.
Si JG; Su YY; Han YH; Chen RH
Genet Test Mol Biomarkers; 2014 Jun; 18(6):394-402. PubMed ID: 24665911
[TBL] [Abstract][Full Text] [Related]
10. Relationships between p16 gene promoter methylation and clinicopathologic features of colorectal cancer: a meta-analysis of 27 cohort studies.
Chen YZ; Liu D; Zhao YX; Wang HT; Gao Y; Chen Y
DNA Cell Biol; 2014 Oct; 33(10):729-38. PubMed ID: 24979649
[TBL] [Abstract][Full Text] [Related]
11. DNA polymorphisms in exon 1 and promoter of the CDH1 gene and relevant risk of transitional cell carcinoma of the urinary bladder.
Ma X; Xu H; Zheng T; Li HZ; Shi TP; Wang BJ; Ju ZH; Wang C; Zhang GX; Zhang X
BJU Int; 2008 Aug; 102(5):633-6. PubMed ID: 18384629
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
13. CDH1 polymorphisms and haplotypes in sporadic diffuse and intestinal gastric cancer: a case-control study based on direct sequencing analysis.
Chu CM; Chen CJ; Chan DC; Wu HS; Liu YC; Shen CY; Chang TM; Yu JC; Harn HJ; Yu CP; Yang MH
World J Surg Oncol; 2014 Mar; 12():80. PubMed ID: 24684952
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis.
Chen F; Huang T; Ren Y; Wei J; Lou Z; Wang X; Fan X; Chen Y; Weng G; Yao X
BMC Urol; 2016 Aug; 16(1):52. PubMed ID: 27578166
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of protocadherin 8 (PCDH8) promoter methylation in non-muscle invasive bladder cancer.
Lin YL; Wang YL; Ma JG; Li WP
J Exp Clin Cancer Res; 2014 Aug; 33(1):68. PubMed ID: 25927589
[TBL] [Abstract][Full Text] [Related]
16. E-cadherin (CDH1) gene -160C/A polymorphism and the risk of colorectal cancer: A meta-analysis involving 17,291 subjects.
Ye CC; Wang J
J Gene Med; 2021 Oct; 23(10):e3370. PubMed ID: 34097324
[TBL] [Abstract][Full Text] [Related]
17. Lack of association between the CDH1 polymorphism and gastric cancer susceptibility: a meta-analysis.
Jiang B; Zhu K; Shao H; Bao C; Ou J; Sun W
Sci Rep; 2015 Jan; 5():7891. PubMed ID: 25599647
[TBL] [Abstract][Full Text] [Related]
18. Association between the Epithelial Cadherin - 160C/A Polymorphism and Colorectal Cancer Risk: Evidence from a Meta-Analysis.
Sun N; Chen J; Hu G; Chen X; Jiang J; Zhang L; Wu H
Crit Rev Eukaryot Gene Expr; 2017; 27(4):347-354. PubMed ID: 29283329
[TBL] [Abstract][Full Text] [Related]
19. The CDH1 -160C/A polymorphism is associated with breast cancer: evidence from a meta-analysis.
Ma YY; Wu WQ; Liu ZC; Yu XF; Guo K; He QW; Jiang SB; Shao QS; Tao HQ; Huang DS
World J Surg Oncol; 2016 Jun; 14(1):169. PubMed ID: 27349965
[TBL] [Abstract][Full Text] [Related]
20. Associations of RASSF1A, RARβ, and CDH1 promoter hypermethylation with oral cancer risk: A PRISMA-compliant meta-analysis.
Wen G; Wang H; Zhong Z
Medicine (Baltimore); 2018 Mar; 97(11):e9971. PubMed ID: 29538221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
